News for Healthier Living

First Patients Enrolled in Groundbreaking Brain Cancer Study at Nationally Recognized Academic Medical Center

Exvade Bioscience(tm), a clinical-stage neuro-oncology company advancing a breakthrough platform for treating aggressive brain cancers, today highlighted ongoing enrollment in a Phase 1 clinical trial (NCT04547777) at the Preston Robert Tisch Brain Tumor Center at Duke University.

January 6, 2026


January 7 2026

January 6 2026

January 5 2026

January 4 2026

January 3 2026

January 2 2026

January 1 2026

December 31 2025

December 30 2025

December 29 2025

December 28 2025

December 27 2025

December 26 2025

December 24 2025